BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
24h
Actuel
Min
119.7
Max
122.55
Revenu | -142M 667M |
---|---|
Ventes | 152M 5.4B |
P/E Moyenne du Secteur | 26.27 57.333 |
BPA | 2.2 |
Rendement du dividende | 1.34 |
Marge bénéficiaire | 12.311 |
EBITDA | 85M 1.6B |
Recommandations | Achat |
---|---|
Prévisions sur 12 Mois | +38.83% upside |
Rendement du dividende Moyenne du Secteur | 1.34% 2.63% |
---|---|
Prochains Résultats | 15 mai 2025 |
Capitalisation Boursière | 33B 98B |
---|---|
Ouverture précédente | 119.98 |
Clôture précédente | 121.4 |
By Trading Central
Confiance
Very Strong Bullish Evidence
117.55 / 120.4 Support & Résistance
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
6 mars 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Lire
11 févr. 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Lire
10 févr. 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Lire
24 avr. 2025, 22:51 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update
DJ
Lire
24 avr. 2025, 20:54 UTC
Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into
DJ
Lire
24 avr. 2025, 20:50 UTC
Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share
DJ
Lire
24 avr. 2025, 19:05 UTC
Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ
DJ
Lire
24 avr. 2025, 19:05 UTC
Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ
DJ
Lire
24 avr. 2025, 19:05 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ
DJ
Lire
24 avr. 2025, 19:05 UTC
Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ
DJ
Lire
6 mars 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Lire
6 mars 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Lire
6 mars 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Lire
6 mars 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Lire
6 mars 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Lire
6 mars 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Lire
11 févr. 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Lire
11 févr. 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Lire
11 févr. 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Lire
6 janv. 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Lire
6 janv. 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Lire
6 janv. 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Lire
Variation de prix
By TipRanks
Prévisions sur 12 Mois
Moyen 166.25 EUR 38.83%
Haut 190 EUR
Bas 107 EUR
Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
By TipRanks
Achat
9 ratings
6
Achat
2
Maintien
1
Vente
Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.
By Trading Central
Court Terme
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Moyen Terme
Bearish Evidence
All events are bearish.
Long Terme
Bearish Evidence
All events are bearish.
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$